Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$28.47 +3.8%	$28.70	$25.56 ▼ $36.45	$4.69B	0.47	1.77 million shs	551,091 shs
BCRX BioCryst Pharmaceuticals	$8.61 +3.1%	$9.21	$6.01 ▼ $11.31	$1.81B	1.1	3.85 million shs	1.56 million shs
FOLD Amicus Therapeutics	$7.23 +3.5%	$6.15	$5.51 ▼ $12.65	$2.23B	0.53	3.86 million shs	3.13 million shs
IONS Ionis Pharmaceuticals	$42.75 +3.2%	$40.22	$23.95 ▼ $50.43	$6.80B	0.25	1.75 million shs	1.53 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+3.35%	+3.12%	-9.41%	-10.42%	+5.74%
BCRX BioCryst Pharmaceuticals	+1.83%	-0.12%	-4.68%	-15.23%	+8.02%
FOLD Amicus Therapeutics	+4.80%	-0.14%	+14.61%	+18.71%	-39.72%
IONS Ionis Pharmaceuticals	+1.40%	-3.81%	-0.77%	+27.02%	-12.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.7839 of 5 stars	4.4	1.0	4.2	3.6	2.5	1.9
BCRX BioCryst Pharmaceuticals	4.1245 of 5 stars	3.5	2.0	4.2	3.1	1.7	0.6
FOLD Amicus Therapeutics	3.915 of 5 stars	3.4	1.0	4.3	2.1	0.0	1.9
IONS Ionis Pharmaceuticals	4.4719 of 5 stars	4.4	3.0	3.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$41.08	44.30% Upside
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	94.07% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	124.53% Upside
IONS Ionis Pharmaceuticals	2.80	Moderate Buy	$58.43	36.68% Upside

Current Analyst Ratings Breakdown

Latest BCRX, IONS, ALKS, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IONS Ionis Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $46.00
8/4/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/31/2025	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$60.00 ➝ $64.00
7/31/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $65.00
7/31/2025	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $62.00
7/30/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$40.00 ➝ $42.00
7/29/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$46.00
7/21/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/15/2025	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.02	$2.84 per share	10.01	$9.84 per share	2.89
BCRX BioCryst Pharmaceuticals	$450.71M	4.01	N/A	N/A	($2.01) per share	-4.28
FOLD Amicus Therapeutics	$528.29M	4.22	N/A	N/A	$0.66 per share	10.95
IONS Ionis Pharmaceuticals	$705M	9.67	N/A	N/A	$3.96 per share	10.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.08	13.66	20.78	1.52	23.15%	24.86%	17.14%	10/23/2025 (Estimated)
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.18	N/A	N/A	1.86	-6.41%	N/A	-1.78%	N/A
FOLD Amicus Therapeutics	-$56.11M	-$0.12	N/A	16.80	N/A	-6.67%	-5.07%	-1.23%	N/A
IONS Ionis Pharmaceuticals	-$453.90M	-$1.84	N/A	N/A	N/A	-28.25%	-45.29%	-8.99%	N/A

Latest BCRX, IONS, ALKS, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.03	$0.15	+$0.12	$0.02	$149.59 million	$163.35 million
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	$0.70	+$0.51	$0.70	$270.90 million	$452.00 million
7/29/2025	Q2 2025	ALKS Alkermes	$0.42	$0.52	+$0.10	$0.52	$343.20 million	$390.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.23	2.85
BCRX BioCryst Pharmaceuticals	N/A	2.25	2.22
FOLD Amicus Therapeutics	1.92	3.21	2.29
IONS Ionis Pharmaceuticals	0.99	2.87	2.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
BCRX BioCryst Pharmaceuticals	85.88%
FOLD Amicus Therapeutics	N/A
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
BCRX BioCryst Pharmaceuticals	5.10%
FOLD Amicus Therapeutics	2.20%
IONS Ionis Pharmaceuticals	2.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	165.08 million	157.82 million	Optionable
BCRX BioCryst Pharmaceuticals	530	209.92 million	199.21 million	Optionable
FOLD Amicus Therapeutics	480	308.24 million	301.46 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.39 million	155.07 million	Optionable

BCRX, IONS, ALKS, and FOLD Headlines

Recent News About These Companies

UBS Group Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock

5 hours ago | marketbeat.com

Ionis Pharmaceuticals price target raised to $46 from $45 at UBS

August 12 at 5:17 PM | msn.com

XTX Topco Ltd Sells 12,958 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

August 11 at 4:41 AM | marketbeat.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director B Lynne Parshall Sells 5,000 Shares

August 10 at 8:43 PM | marketbeat.com

Leerink Partnrs Has Negative Outlook of IONS Q3 Earnings

August 9, 2025 | marketbeat.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Sells $209,650.00 in Stock

August 9, 2025 | insidertrades.com

Commerce Bank Reduces Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

August 9, 2025 | marketbeat.com

Q3 EPS Estimate for Ionis Pharmaceuticals Reduced by Analyst

August 9, 2025 | americanbankingnews.com

Richard S. Geary Sells 10,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

August 7, 2025 | marketbeat.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard S. Geary Sells 10,000 Shares

August 7, 2025 | insidertrades.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc.

August 7, 2025 | marketbeat.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $408,697.20 in Stock

August 6, 2025 | marketbeat.com

Eugene Schneider Sells 9,549 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

August 6, 2025 | insidertrades.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Raiffeisen Bank International AG

August 6, 2025 | marketbeat.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Acquires Shares of 8,059 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

August 6, 2025 | marketbeat.com

Jefferies Financial Group Inc. Sells 2,696,240 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

August 6, 2025 | marketbeat.com

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

August 4, 2025 | finance.yahoo.com

Brett P. Monia Sells 2,432 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

August 2, 2025 | marketbeat.com

Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells 2,432 Shares of Stock

August 2, 2025 | insidertrades.com

Ionis Pharmaceuticals (NASDAQ:IONS) Given New $64.00 Price Target at Raymond James Financial

August 1, 2025 | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Given New $65.00 Price Target at HC Wainwright

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BCRX, IONS, ALKS, and FOLD Company Descriptions

Alkermes NASDAQ:ALKS

$28.47 +1.04 (+3.80%)

As of 02:32 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.60 +0.26 (+3.05%)

As of 02:32 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics NASDAQ:FOLD

$7.22 +0.25 (+3.51%)

As of 02:31 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ionis Pharmaceuticals NASDAQ:IONS

$42.75 +1.34 (+3.24%)

As of 02:32 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time